IN202121042020A - - Google Patents
Download PDFInfo
- Publication number
- IN202121042020A IN202121042020A IN202121042020A IN202121042020A IN202121042020A IN 202121042020 A IN202121042020 A IN 202121042020A IN 202121042020 A IN202121042020 A IN 202121042020A IN 202121042020 A IN202121042020 A IN 202121042020A IN 202121042020 A IN202121042020 A IN 202121042020A
- Authority
- IN
- India
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202121042020A IN202121042020A (fr) | 2021-09-17 | 2021-09-17 | |
CA3229273A CA3229273A1 (fr) | 2021-09-17 | 2022-09-15 | Formulation pharmaceutique injectable, stable et prete a diluer de mitomycine |
AU2022347385A AU2022347385A1 (en) | 2021-09-17 | 2022-09-15 | A stable ready to dilute injectable pharmaceutical formulation of mitomycin |
EP22869512.8A EP4401727A1 (fr) | 2021-09-17 | 2022-09-15 | Formulation pharmaceutique injectable, stable et prête à diluer de mitomycine |
JP2024509340A JP2024531333A (ja) | 2021-09-17 | 2022-09-15 | マイトマイシンの安定なすぐに希釈できる注射用医薬製剤 |
PCT/IB2022/058697 WO2023042107A1 (fr) | 2021-09-17 | 2022-09-15 | Formulation pharmaceutique injectable, stable et prête à diluer de mitomycine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202121042020A IN202121042020A (fr) | 2021-09-17 | 2021-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN202121042020A true IN202121042020A (fr) | 2023-03-24 |
Family
ID=85602499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN202121042020A IN202121042020A (fr) | 2021-09-17 | 2021-09-17 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4401727A1 (fr) |
JP (1) | JP2024531333A (fr) |
AU (1) | AU2022347385A1 (fr) |
CA (1) | CA3229273A1 (fr) |
IN (1) | IN202121042020A (fr) |
WO (1) | WO2023042107A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024079565A1 (fr) * | 2022-10-12 | 2024-04-18 | Harshal Prabhakar Bhagwatwar | Concentrés stables de mitomycine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6630168B1 (en) * | 1997-02-20 | 2003-10-07 | Biomedicines, Inc. | Gel delivery vehicles for anticellular proliferative agents |
DE19957371A1 (de) * | 1999-11-29 | 2001-06-13 | Medac Klinische Spezialpraep | Mitomycin C-Lösung |
ES2771227T3 (es) * | 2013-10-22 | 2020-07-06 | Medac Ges Fuer Klinische Spezialpraeparate Mbh | Procedimiento de preparación de una composición farmacéutica liofilizada que contiene mitomicina C |
-
2021
- 2021-09-17 IN IN202121042020A patent/IN202121042020A/en unknown
-
2022
- 2022-09-15 WO PCT/IB2022/058697 patent/WO2023042107A1/fr active Application Filing
- 2022-09-15 AU AU2022347385A patent/AU2022347385A1/en active Pending
- 2022-09-15 JP JP2024509340A patent/JP2024531333A/ja active Pending
- 2022-09-15 EP EP22869512.8A patent/EP4401727A1/fr active Pending
- 2022-09-15 CA CA3229273A patent/CA3229273A1/fr active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024079565A1 (fr) * | 2022-10-12 | 2024-04-18 | Harshal Prabhakar Bhagwatwar | Concentrés stables de mitomycine |
Also Published As
Publication number | Publication date |
---|---|
EP4401727A1 (fr) | 2024-07-24 |
AU2022347385A1 (en) | 2024-02-22 |
CA3229273A1 (fr) | 2023-03-23 |
WO2023042107A1 (fr) | 2023-03-23 |
JP2024531333A (ja) | 2024-08-29 |